Paul Choi
Stock Analyst at Goldman Sachs
(4.01)
# 576
Out of 5,117 analysts
116
Total ratings
55.26%
Success rate
11.19%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Maintains: Buy | $55 → $95 | $53.58 | +77.30% | 1 | Dec 19, 2025 | |
| CYTK Cytokinetics | Upgrades: Buy | $55 → $95 | $63.11 | +50.53% | 3 | Dec 19, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $44 → $50 | $78.52 | -36.32% | 8 | Nov 5, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $55 → $100 | $75.80 | +31.93% | 7 | Oct 31, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $55 | $42.00 | +30.95% | 2 | Oct 29, 2025 | |
| ARVN Arvinas | Downgrades: Sell | $8 → $6 | $12.16 | -50.66% | 4 | Oct 15, 2025 | |
| LNTH Lantheus Holdings | Downgrades: Neutral | $110 → $77 | $66.71 | +15.42% | 2 | Oct 8, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Neutral | $20 | $26.35 | -24.10% | 1 | Sep 25, 2025 | |
| EXEL Exelixis | Initiates: Buy | $47 | $46.24 | +1.64% | 1 | Sep 17, 2025 | |
| AMRN Amarin Corporation | Maintains: Sell | $7 → $12 | $14.14 | -15.13% | 9 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $3 | $23.03 | -86.97% | 4 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $8 | $3.23 | +147.68% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $5 | $17.56 | -71.53% | 10 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $52 | $44.84 | +15.97% | 2 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $6.00 | +250.00% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $12 | $14.16 | -15.25% | 3 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $4.04 | -25.74% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $12 → $10 | $15.38 | -34.98% | 4 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $208.98 | +7.67% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $13.76 | +38.08% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $5.40 | +251.85% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $400 → $50 | $8.90 | +461.80% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.24 | +1,916.13% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $11.15 | +1,424.66% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $6.16 | +29.87% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $145.26 | -7.06% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $44.49 | +574.31% | 2 | Mar 30, 2020 |
Vera Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $95
Current: $53.58
Upside: +77.30%
Cytokinetics
Dec 19, 2025
Upgrades: Buy
Price Target: $55 → $95
Current: $63.11
Upside: +50.53%
PTC Therapeutics
Nov 5, 2025
Maintains: Sell
Price Target: $44 → $50
Current: $78.52
Upside: -36.32%
BridgeBio Pharma
Oct 31, 2025
Maintains: Buy
Price Target: $55 → $100
Current: $75.80
Upside: +31.93%
Kiniksa Pharmaceuticals International,
Oct 29, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $42.00
Upside: +30.95%
Arvinas
Oct 15, 2025
Downgrades: Sell
Price Target: $8 → $6
Current: $12.16
Upside: -50.66%
Lantheus Holdings
Oct 8, 2025
Downgrades: Neutral
Price Target: $110 → $77
Current: $66.71
Upside: +15.42%
Edgewise Therapeutics
Sep 25, 2025
Initiates: Neutral
Price Target: $20
Current: $26.35
Upside: -24.10%
Exelixis
Sep 17, 2025
Initiates: Buy
Price Target: $47
Current: $46.24
Upside: +1.64%
Amarin Corporation
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $14.14
Upside: -15.13%
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $23.03
Upside: -86.97%
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $3.23
Upside: +147.68%
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $17.56
Upside: -71.53%
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $44.84
Upside: +15.97%
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $6.00
Upside: +250.00%
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $14.16
Upside: -15.25%
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $4.04
Upside: -25.74%
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $15.38
Upside: -34.98%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $208.98
Upside: +7.67%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $13.76
Upside: +38.08%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $5.40
Upside: +251.85%
Jun 27, 2023
Maintains: Sell
Price Target: $400 → $50
Current: $8.90
Upside: +461.80%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.24
Upside: +1,916.13%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $11.15
Upside: +1,424.66%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $6.16
Upside: +29.87%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $145.26
Upside: -7.06%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $44.49
Upside: +574.31%